Marker composition based on exosomes overexpressing TUBA1C protein

By measuring the expression levels of TUBA1C and GCC2 proteins in exosomes in cancer patients, combined with specific primers and antibodies, the problem of insufficient sensitivity and specificity of cancer diagnosis in the prior art is solved, and lung cancer, thymic cancer and esophageal tubes are realized Accurate diagnosis and prognosis prediction of cancer improves the sensitivity and accuracy of diagnosis.

CN113785200BActive Publication Date: 2024-12-03KOREA UNIV RES & BUSINESS FOUND +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202080024586.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-03
Filing Date
2020-04-03
Publication Date
2024-12-03
Estimated Expiration
2040-04-03

AI Technical Summary

Technical Problem

The prior art lacks high sensitivity and specificity in cancer diagnosis, and the examination process is not non-invasive and accurate, making it difficult to detect specific cancers in the early stage.

Method used

Develop a marker composition including exosomes and GCC2 proteins overexpressing the TUBA1C protein, by measuring the expression levels of these proteins, non-invasive diagnosis using specific primers, probes and antibodies, combined with RT-PCR, microscopy Array chips and other kits are tested.

Benefits of technology

Accurate diagnosis and prognosis prediction of lung cancer, thymic cancer and esophageal cancer are achieved, which improves the sensitivity and accuracy of cancer diagnosis and provides the possibility of early detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113785200B_ABST
    Figure CN113785200B_ABST
Patent Text Reader

Abstract

According to one embodiment of the present invention, there is provided a marker composition for diagnosing cancer or predicting prognosis, comprising exosomes overexpressing tubulin alpha-1C chain (TUBA1C) protein, a kit, and a method for providing information required for diagnosing cancer or predicting prognosis, comprising the step of measuring the expression level of the TUBA1C gene or protein in exosomes isolated from a biological sample.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a marker composition for diagnosing cancer or predicting prognosis, comprising exosomes overexpressing alpha-tubulin 1C chain (TUBA1C) protein. Background Art

[0002] A tumor is the product of uncontrolled and disordered cell proliferation caused by an excess of abnormal cells. When such a tumor proliferates, spreads and metastasizes destructively, it will be classified as a malignant tumor, or cancer.

[0003] Currently, cancer is diagnosed by X-ray, endoscopy, pathological examination, etc. Although the above examination methods are relatively simple, the diagnosis success rate is not high, there are hygiene problems, and the patient will feel pain during the examination. Therefore, it is necessary to develop a cancer diagnosis method that can replace the above methods.

[0004] In order to treat cancer, highly sensitive and specific cancer diagnosis is required before treatment. Only by detecting cancer at an early stage through such diagnosis can the cure rate be improved.

[0005] Therefore, there is a need to develop a method that can non-invasively diagnose cancer at an early stage with high sensitivity and specificity. However, there is still a lack of molecular diagnostic technology that can specifically detect lesions at an early stage and thus determine whether the disease has occurred. In particular, a method that is specifically applicable to a specific cancer has not yet been developed.

[0006] Prior patent documents

[0007] Patent Literature

[0008] Korean Patent No. 10-2080887

[0009] Summary of the invention

[0010] Technical issues to be solved

[0011] In this context, the present inventors have continued their research to develop new exosome-derived markers for diagnosing cancer or predicting prognosis. As a result, they have confirmed that when the TUBA1C (Tubulin alpha-1C chain) protein specifically expressed in exosomes derived from cancer cells is used, cancer can be accurately and quickly diagnosed or prognosis can be predicted, thereby completing the present invention.

[0012] The object of the present invention is to provide a marker composition capable of improving the accuracy of cancer diagnosis by a non-invasive method, wherein the composition comprises exosomes based on overexpression of TUBA1C protein, and also provides a method for using the composition to provide information required for diagnosing cancer or predicting prognosis.

[0013] However, the problems to be solved by the present invention are not limited to the above-mentioned technical problems, and other technical problems not mentioned can be clearly understood by ordinary technicians in this field through the following description.

[0014] Technical methods to solve problems

[0015] According to one embodiment of the present invention, a marker composition for diagnosing cancer or predicting prognosis is provided, comprising exosomes overexpressing TUBA1C (Tubulin alpha-1C chain) protein.

[0016] According to one aspect, the exosomes further include GCC2 (GRIP and coiled-coil domain-containing protein) protein.

[0017] According to one aspect, the cancer is lung cancer, thymic cancer or esophageal cancer.

[0018] According to another embodiment of the present invention, a composition for diagnosing cancer or predicting prognosis is provided, comprising any one or more of a primer or a probe that specifically binds to TUBA1C protein in exosomes; and an antibody that specifically binds to TUBA1C protein in exosomes.

[0019] According to one aspect, the composition further comprises any one or more of a primer or a probe that specifically binds to the GCC2 gene in the exosome; and an antibody that specifically binds to the GCC2 protein in the exosome.

[0020] According to one aspect, the cancer is lung cancer, thymic cancer or esophageal cancer.

[0021] According to another embodiment of the present invention, a kit for diagnosing cancer or predicting prognosis comprising the composition is provided.

[0022] According to one aspect, the kit is one or more selected from the group consisting of an RT-PCR kit, a microarray chip kit, a DNA kit, and a protein chip kit.

[0023] According to another embodiment of the present invention, a method for providing information required for diagnosing cancer or predicting prognosis is provided, comprising the step of measuring the expression level of TUBA1C gene or protein in exosomes isolated from a biological sample.

[0024] According to one aspect, the method further includes a step of measuring the expression level of the GCC2 gene or protein in the exosomes.

[0025] According to one aspect, the biological sample is one or more selected from the group consisting of whole blood, serum, plasma, saliva, urine, sputum, lymph fluid and cells.

[0026] Effects of the Invention

[0027] The marker composition of the present invention includes TUBA1C protein overexpressed in the exosomes of cancer patients, and by measuring the expression level thereof, cancer can be accurately diagnosed or prognosis can be predicted non-invasively.

[0028] Furthermore, the marker composition of the present invention uses TUBA1C and GCC2 overexpressed in exosomes as dual biomarkers, which can further improve the sensitivity and accuracy of cancer diagnosis.

[0029] However, the effects intended by the present invention are not limited to the above effects, but should include all effects that can be derived based on the specific embodiments of the present invention or the description of the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The results of ELISA were compared between the expression levels of GCC2 and TUBA1C proteins in the blood-derived exosomes of lung cancer patients and those of the normal control group.

[0031] Figure 2 This is the ELISA result comparing the expression level of TUBA1C protein in plasma-derived exosomes of patients with esophageal cancer with that of the normal control group.

[0032] Figure 3 The results of ELISA comparing the expression level of TUBA1C protein in plasma-derived exosomes of thymic carcinoma patients with that of the normal control group.

[0033] Figure 4 These are the ELISA results for measuring the expression levels of TUBA1C and GCC2 in plasma-derived exosomes from lung cancer patients according to the stage.

[0034] Figure 5 The figure is a ROC curve that confirms the change in sensitivity for lung cancer diagnosis when TUBA1C and GCC2 are used alone and when both markers are used. DETAILED DESCRIPTION

[0035] The embodiments are described in detail below with reference to the accompanying drawings. The same reference numerals in the drawings represent the same components.

[0036] The embodiments described below can be modified in many ways. The implementation of the present invention is not limited to the following embodiments, but should include all modifications, equivalents and even substitutes of the following embodiments.

[0037] The terms used in the implementation are only used to illustrate specific embodiments and are not used to limit the scope of protection. In the absence of special instructions in the content, singular expressions include plural meanings. In this specification, the terms "including" or "having" are used to express the existence of features, numbers, steps, operations, constituent elements, accessories or combinations thereof recorded in the specification, and do not exclude the presence of one or more other features, numbers, steps, operations, constituent elements, accessories or combinations thereof or additional functions.

[0038] In the absence of other definitions, all terms used in this specification, including technical or scientific terms, have the common meanings understood by ordinary technicians in the field. Commonly used terms as defined in dictionaries should be understood as the meanings in the relevant technical content, and should not be interpreted as idealized or overly formalized meanings if they are not clearly defined in this specification.

[0039] Furthermore, in the process of describing with reference to the drawings, the same components are denoted by the same reference numerals regardless of the reference numerals, and repeated descriptions are omitted. In the process of describing the embodiments, when it is determined that the detailed description of the related known technology will unnecessarily confuse the embodiments, its detailed description is omitted.

[0040] According to one embodiment of the present invention, a marker composition for diagnosing cancer or predicting prognosis is provided, which includes exosomes that overexpress TUBA1C (Tubulin alpha-1C chain) protein. In addition, the exosomes may also include GRIP and coiled-coil domain-containing protein 2 (GRIP and coiled-coil domain-containing protein, GCC2) protein.

[0041] The terms “exosomes overexpressing TUBA1C protein” and “exosomes overexpressing GCC2 protein” used herein refer to exosomes capable of expressing GCC2 or TUBA1C protein at a higher level than exosomes present in normal cells.

[0042] Exosomes are small membrane vesicles of nanometer size (30-150nm) secreted by most cells. It is well known that the interior of exosomes and the phospholipid bilayer membrane contain a variety of proteins, genetic materials (DNA, mRNA, miRNA), lipids, etc. derived from cells. In addition, exosomes derived from tissues can reflect the state of the tissues that secrete them, so they can be used to diagnose diseases.

[0043] Thus, the present inventors have found that cancer can be accurately and rapidly diagnosed or the prognosis can be predicted using TUBA1C or GCC2 proteins specifically expressed in exosomes of cancer patients, thereby completing the present invention.

[0044] Cancer here includes all cancers, non-limiting examples include lung cancer, esophageal cancer, thymic cancer, breast cancer, liver cancer, stomach cancer, rectal cancer, pancreatic cancer, cervical cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, bladder cancer, head and neck cancer, bone marrow cancer, bile duct cancer, among which lung cancer, esophageal cancer or thymic cancer is preferred.

[0045] The term "diagnosis" used in this specification refers to confirming the presence or absence of a pathological state or the characteristics of a pathological state, that is, confirming whether a person has cancer. In addition, "prognosis" refers to determining whether a corresponding individual has recurrence, metastasis, drug response, drug resistance, etc. after cancer treatment. That is, by measuring the expression level of TUBA1C or GCC2 in exosomes isolated from individual samples, it is possible to determine whether the corresponding individual has cancer and predict whether the prognosis of the corresponding individual after survival is good.

[0046] Thus, cancer can be diagnosed or prognosis can be predicted by measuring the expression level of TUBA1C or GCC2 protein derived from exosomes, and primers or probes that specifically bind to the gene, or antibodies that specifically bind to the protein can be used as compositions for diagnosing cancer or predicting prognosis.

[0047] Furthermore, the present invention can provide a kit for diagnosing cancer or predicting prognosis by applying any one or more of a primer or a probe that specifically binds to the TUBA1C or GCC2 gene or an antibody that specifically binds to the TUBA1C or GCC2 protein to the kit.

[0048] Non-limiting examples of the kit may include RT-PCR kits, microarray chip kits, DNA kits, protein chip kits, etc. The kit can confirm and detect the expression levels of TUBA1C and GCC2 proteins equivalent to markers in exosomes, thereby diagnosing cancer or predicting prognosis.

[0049] For the purpose of diagnosing cancer or predicting prognosis, the kit includes primers, probes or antibodies that selectively recognize the markers, and further includes a composition, solution or device of one or more other components suitable for use in the analytical method.

[0050] For example, in order to perform immunological detection of antibodies, the kit may include a substrate, a suitable buffer solution, a secondary antibody labeled with a colorimetric enzyme or a fluorescent substance, and a colorimetric substrate, etc. In addition, as a substrate, a nitrocellulose membrane, a 96-well plate synthesized from a polyethylene resin, a 96-well plate synthesized from a polystyrene resin, and a glass slide made of glass may be used; the colorimetric enzyme may use peroxidase, alkaline phosphatase, etc.; the fluorescent substance may use fluorescein isothiocyanate (FITC), rhodamine isothiocyanate (RITC), etc.; the colorimetric substrate may use ABTS (2,2-azino-di(3-ethyl-benzothiazole-6-sulfonic acid) diammonium salt) or OPD (o-phenylenediamine), TMB (tetramethylbenzidine), but is not limited thereto.

[0051] According to another embodiment of the present invention, a method for providing information required for diagnosing cancer or predicting cancer is provided, comprising the following steps: measuring the expression level of TUBA1C gene or protein in exosomes isolated from a biological sample.

[0052] In order to improve the sensitivity and accuracy of cancer diagnosis, the method of the present invention may further include the step of measuring the expression level of the GCC2 gene or protein in the exosomes.

[0053] The biological sample may be one or more selected from the group consisting of whole blood, serum, plasma, saliva, urine, sputum, lymph fluid, and cells, and preferably may be whole blood or cells, but is not limited thereto.

[0054] Measuring gene expression levels is a process of confirming the presence or expression level of TUBA1C and GCC2 gene mRNA in a biological sample in order to diagnose cancer or predict prognosis, that is, measuring the mRNA expression level.

[0055] Non-limiting examples of analytical methods used for this purpose include reverse transcription-polymerase chain reaction (RT-PCR), competitive RT-PCR, real-time RT-PCR, RNase protection assay (RPA), Northern blotting, DNA chip, etc.

[0056] Furthermore, measuring the expression level of the protein is a process of confirming the presence of TUBA1C and GCC2 proteins and their expression levels in a biological sample in order to diagnose cancer or predict prognosis.

[0057] Non-limiting examples of the method for measuring the expression level of the protein or the comparative analysis method include: protein chip analysis, immunoassay, ligand binding analysis, matrix-assisted laser desorption / ionization time of flight mass spectrometry (MALDI-TOF) analysis, surface enhanced laser desorption / ionization time of flight mass spectrometry (SELDI-TOF) analysis, radioimmunoassay, radial immunodiffusion, ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistostaining, complement fixation, two-dimensional electrophoresis, liquid chromatography-mass spectrometry (LC-MS), liquid chromatography-mass spectrometry / mass spectrometry (LC-MS / MS), Western blot and enzyme-linked immunosorbent assay (ELISA). immunosorbent assay, ELISA), etc.

[0058] After measuring the gene or protein expression levels of the TUBA1C and GCC2, they are compared with the normal control group. When the expression levels are higher than those of the normal control group, it can be determined that cancer has occurred or is more likely to occur.

[0059] Furthermore, according to one embodiment of the present invention, a method for screening cancer therapeutic agents is provided, comprising the following steps: (a) applying a candidate cancer therapeutic agent substance to a biological sample collected from a cancer patient; (b) isolating exosomes from the biological sample; and (c) measuring the expression level of the TUBA1C gene or protein in the exosomes.

[0060] The method for providing the information required for diagnosing cancer or predicting prognosis can be extended to be used for screening the candidate therapeutic agent. That is, after applying the candidate cancer therapeutic agent to a biological sample isolated from a cancer patient, when it is confirmed that the expression level of the TUBA1C gene or protein in the exosomes therein is reduced, it can be confirmed that the corresponding candidate substance has an effective function as a cancer therapeutic agent.

[0061] The present invention will be described in more detail below by way of examples. The following examples are used to illustrate the present invention, but the scope of the present invention is not limited thereto.

[0062] Example 1: Preparation for Isolation of Exosomes and Proteome Analysis

[0063] Five cancer cell lines (H522, A549, H1650, PC9, H1299), thymic cancer cell lines, and esophageal cancer cell lines were cultured in 150 mm diameter culture dishes. At this time, ultra-high speed centrifuge was used for centrifugation at 120000g for 4 hours, and the supernatant of fetal bovine serum (FBS) from which exosomes were removed was used as culture medium. The culture medium was used for continuous culture for 2-3 days until the cell confluence reached 70-80%.

[0064] The obtained culture medium was centrifuged at 10000g for 30 minutes to remove cell debris, and then passed through 0.45μm and 0.22μm filters in sequence to preferentially remove larger substances. Afterwards, the filtered cell culture medium was concentrated using Amicon tube 100K (Millipore, USA) to retain only particles of the desired size.

[0065] Afterwards, the concentrated cell culture medium was separated into exosome-sized particles (50-100 nm) using column liquid chromatography and concentrated again using Amicon tube 100K.

[0066] Proteins were obtained from concentrated exosomes using RIPA lysis buffer (Thermo Fisher Scientific, USA), and the results of proteomic analysis were commissioned to the Korea Basic Science Institute (KBSI).

[0067] Based on this, TUBA1C (Tubulinalpha-1C chain) and GCC2 (GRIP and coiled-coil domain-containing protein 2) that were overexpressed in the exosomes of cancer cell lines were finally screened out.

[0068] Example 2: Measurement of the expression levels of GCC2 and TUBA1C proteins in exosomes of lung cancer patients

[0069] In order to confirm whether the exosomes containing GCC2 and TUBA1C proteins screened in Example 1 are feasible as markers for diagnosing lung cancer or predicting prognosis, the expression levels of GCC2 and TUBA1C in exosomes extracted from the blood of the normal group (n=3) and the lung cancer patient group (n=5) were analyzed by ELISA (Enzyme linked immunoassay).

[0070] The result, as in Figure 1 As shown in , the expression of GCC2 and TUBA1C in the lung cancer patient group was increased compared with the normal group (control).

[0071] Afterwards, in order to confirm the characteristics of exosomes isolated from the plasma of lung cancer patients, blood was collected from 20 patients with stage 1 to stage 3 lung cancer in the hospital, and exosomes were isolated from the plasma using Exoquick (Systembio, USA). The expression levels of GCC2 and TUBA1C in exosomes derived from the isolated blood were confirmed by ELISA (GCC2: GRIP and coiled-coil domain containing proten 2 from Mybiosource; ELISA KIT (Cat No.MBS9330667), 2) TUBA1C: TUBA1C ELISA KIT (Cat No.MBS9336377) from Mybiosource). The results showed that Figure 4 As shown, compared with the normal group, the expression levels of GCC2 and TUBA1C were significantly increased in all lung cancer stages, and as the lung cancer stage increased, the expression levels of GCC2 and TUBA1C also increased.

[0072] Example 3: Measurement of TUBA1C expression levels in exosomes of patients with esophageal cancer and thymic cancer

[0073] First, exosomes were extracted from plasma samples of 5 normal subjects and 5 esophageal cancer patients, and then the TUBA1C protein concentration in the samples was confirmed using TUBA1C ELISA KIT (TUBA1C ELISA KIT (Cat No. MBS9336377) from Mybiosource).

[0074] The results are as follows Figure 2 As shown, the average concentration of TUBA1C protein derived from exosomes of normal people is 939.306ng / ml, while the average concentration of TUBA1C protein derived from exosomes of esophageal cancer patients is higher at 1236.764ng / ml. The concentration of TUBA1C protein derived from exosomes of esophageal cancer patients is 1.36 times higher than that of normal people, with a p value of 0.021, which is statistically significant.

[0075] Then, exosomes were extracted from plasma samples of 5 normal subjects and 5 thymic cancer patients, and the TUBA1C protein concentration in the samples was confirmed using TUBA1C ELISA KIT (TUBA1C ELISA KIT (Cat No. MBS9336377) from Mybiosource).

[0076] The results are as follows Figure 3 As shown, the average concentration of TUBA1C protein derived from exosomes of normal people is 939.306ng / ml, while the average concentration of TUBA1C protein derived from exosomes of esophageal cancer patients is very high, which is 3503.15ng / ml. The concentration of TUBA1C protein derived from exosomes of esophageal cancer patients is 3.85 times higher than that of normal people, with a p value of 0.005, which is statistically significant.

[0077] Example 4: Evaluation of diagnostic effectiveness when TUBA1C and GCC2 are used as dual biomarkers

[0078] In order to evaluate the effectiveness of using TUBA1C and GCC2 as dual biomarkers in diagnosing cancer, the ROC curve was used to confirm the change in diagnostic sensitivity when TUBA1C and GCC2 were used alone and when both markers were used simultaneously. Specifically, exosomes were extracted from the plasma of 7 normal subjects and 21 lung cancer patients, and the concentrations of GCC2 and TUBA1C proteins in exosomes were obtained using GCC2 ELISA KIT and TUBA1C ELISA KIT. The AUC value was confirmed using a statistical ROC curve and displayed. Figure 5 middle.

[0079] Reference Figure 5 When GCC2 antibody was used alone, the AUC was 0.905 (p=0.002), and when TUBA1C antibody was used alone, the AUC was 0.8787 (p=0.003). In contrast, when GCC2 and TUBA1C antibodies were used simultaneously, the AUC was 1 (P0.0000963). Using TUBA1C and GCC2 as dual biomarkers allowed for more accurate diagnosis than using TUBA1C or GCC2 alone.

[0080] In summary, the embodiments are described through limited drawings, and a person skilled in the art can make various technical modifications and variations based on the description. For example, the described techniques are performed in a different order from the described method, and / or the described constituent elements are combined or combined in a different form from the described method, or replaced or substituted by other constituent elements or equivalents, and appropriate results can also be obtained.

[0081] Accordingly, other embodiments, other examples, and their equivalents are within the scope of the appended claims.

Claims

1. A marker composition for diagnosing cancer or predicting prognosis, characterized in that: including exosomes overexpressing TUBA1C protein; Wherein, the exosomes also include GCC2 protein.

2. The marker composition for diagnosing cancer or predicting prognosis according to claim 1, characterized in that: The cancer is lung cancer, thymic cancer or esophageal cancer.

3. A composition for diagnosing cancer or predicting prognosis, characterized in that: It includes a primer or a probe that specifically binds to the TUBA1C gene in the exosome, or an antibody that specifically binds to the TUBA1C protein in the exosome; The composition further includes a primer or a probe that specifically binds to the GCC2 gene in the exosome, or an antibody that specifically binds to the GCC2 protein in the exosome.

4. The composition for diagnosing cancer or predicting prognosis according to claim 3, characterized in that: The cancer is lung cancer, thymic cancer or esophageal cancer.

5. A kit for diagnosing cancer or predicting prognosis, characterized in that: Comprising the composition of claim 3 or 4.

6. The kit for diagnosing cancer or predicting prognosis according to claim 5, The kit is one or more selected from the group consisting of an RT-PCR kit, a microarray chip kit, a DNA kit and a protein chip kit.

7. Use of a reagent for detecting the expression level of TUBA1C gene or protein and a reagent for detecting the expression level of GCC2 gene or protein in the preparation of a kit for diagnosing cancer or predicting prognosis.

8. The use of claim 7, wherein The reagent for detecting the expression level of the GCC2 gene or protein includes a primer or a probe that specifically binds to the GCC2 gene in the exosome, or an antibody that specifically binds to the GCC2 protein in the exosome.

9. The use of claim 7, wherein The kit diagnoses cancer or predicts prognosis by measuring the expression level of the TUBA1C gene or protein in exosomes separated from a biological sample, and measuring the expression level of the GCC2 gene or protein in the exosomes.

10. Use of a reagent for detecting the expression level of TUBA1C gene or protein in the preparation of a kit for diagnosing thymic cancer or esophageal cancer, or predicting prognosis.

11. The use according to claim 7 or 10, wherein The reagent for detecting the expression level of TUBA1C gene or protein includes a primer or probe that specifically binds to the TUBA1C gene in the exosome, or an antibody that specifically binds to the TUBA1C protein in the exosome.

12. The use according to claim 10, wherein The kit diagnoses esophageal cancer or thymic cancer, or predicts prognosis, by measuring the expression level of the TUBA1C gene or protein in exosomes separated from a biological sample.

13. The use according to claim 9 or 12, characterized in that: The biological sample is one or more selected from the group consisting of whole blood, serum, plasma, saliva, urine, sputum, lymph fluid and cells.

Citation Information

Patent Citations

  • Composition for diagnosing or prognosing lung cancer including exosome based gcc2 gene and protein

    KR102080887B1

  • Circulating biomarkers for disease

    US20140162888A1